New Research from Netradyne Highlights Untapped Potential of AI to Boost Fleet Safety
4.11.2024 10:00:00 CET | Business Wire | Press Release
Delegate research conducted by Netradyne at the Gartner Supply Chain Planning Summit last week has revealed the untapped potential of artificial intelligence (AI) to boost fleet safety for greater precision and profitability in supply chain logistics and transportation. Currently, only 33% of respondents use AI to assess and monitor fleet safety performance. However, 81% plan to adopt AI platforms within the next year to mitigate risks and enhance safety for improved operational performance.
The challenges facing third party logistics providers
The survey highlights accuracy, timeliness and cost-effectiveness as the top priorities in goods delivery, named by 57% and 31% of supply chain professionals respectively. However, despite the importance of logistics and transportation precision, companies face persistent obstacles, with a lack of fleet visibility and limited driver availability cited as major factors hampering delivery accuracy.
Accidents are another critical issue, contributing to product damage in transit, damaging the brand image, impacting driver well-being and availability, and driving up costs. Alarmingly, 46% of respondents were uncertain of the total financial impact of accidents on their businesses.
Outdated technologies limit data accuracy
Data is critical for fleet management and safety, with 52% of respondents already sharing data with partners to improve safety standards. However, many current systems rely on outdated technologies, such as telematics and GPS, which have limited functionality. As shown by the significant leap in those planning to adopt AI in fleet safety management, supply chain teams increasingly recognise the value of AI-driven data for its precision and ability to provide more meaningful insights into fleet operations.
AI-driven data: The key to safer, more efficient fleet operations
Integrating AI tools into goods delivery processes offers significant benefits. AI-driven solutions can enhance delivery precision and timeliness by improving fleet visibility and driver availability. They can analyse data to predict and prevent accidents, reduce traffic violations and enhance driver behaviour. By enabling data-driven fleet engagement, AI contributes to a safer and more efficient fleet, providing third-party logistics (3PL) providers with better oversight and control over their operations and significantly reducing costs. These cost savings directly impact profitability, making AI an invaluable asset.
“Transportation is an inherently tough business. With more people on the road and unpredictable conditions, there is more risk for logistics providers than ever. Challenges like growing end-customer expectations for quick and hassle-free delivery, rising costs, shrinking markets and increasingly selective insurers add to the pressures faced by supply chain teams. Visibility in fleet operations is crucial to managing these challenges, and AI is proving to be a key tool for improving it,” commented Durgadutt Nedungadi, Sr. Vice-President for International Business at Netradyne.
“Vision-based AI technologies can help alleviate many of these challenges by delivering real-time insights that boost safety, predict potential issues, and ensure timely interventions. As the industry grows more complex, supply chain leaders are increasingly turning to AI-driven data analysis to boost operational efficiency, improve safety, and maintain a competitive edge,” concluded Durgadutt.
Notes to editor:
The research, conducted by Liberty Comms Ltd on behalf of Netradyne, surveyed 101 Supply Chain professionals at the Gartner Supply Chain Planning event in London on October 14th & 15th 2024.
About Netradyne:
Netradyne Technology is a global provider of video telematics and an industry leader in fleet safety solutions. Driver•i, Netradyne’s AI fleet camera system, detects potential hazards, helping drivers make safer decisions and reducing risky behavior by up to 99%. Netradyne’s relentless pursuit of technological advancements and its unwavering dedication to improving road safety have positioned the company as a leader in the field. With its innovative AI and ML-based IoT solution, the company continues to empower organizations worldwide to create safer road environments, protect lives, and build a sustainable future. Stay up to date with Netradyne on LinkedIn, Facebook, our blog, and in our newsroom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104368650/en/
Contacts
netradyne@libertycomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom